Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time†
Open Access
- 28 May 2009
- journal article
- viral hepatitis
- Published by Wolters Kluwer Health in Hepatology
- Vol. 49 (6) , 1859-1867
- https://doi.org/10.1002/hep.22878
Abstract
The baseline alanine aminotransferase (ALT) level was reported to have prognostic value in chronic hepatitis B virus (HBV) infection, during which ALT may change over time. Instead of baseline ALT, this study aimed to study the prognostic value of the height of ALT during the course of chronic HBV infection. A total of 4376 asymptomatic hepatitis B e antigen (HBeAg) negative, surface antigen (HBsAg) carriers with baseline ALT less than 2 times the upper limit of normal (ULN) were monitored with ALT measurement and ultrasonography every 3 to 12 month for over 3 years. Maximal ALT levels during follow‐up were correlated with long‐term outcomes using morbidity and mortality data from hospital records, cancer registration, and national mortality database. Baseline ALT level was normal in 3673 subjects and increased to abnormal level in 1720 (46.8%) during a mean follow‐up period of 13.4 ± 5.2 (3.0‐28.7) years. The incidence of liver cirrhosis, hepatocellular carcinoma (HCC), and mortality increased with increasing maximal ALT level during follow‐up, especially in those with maximal ALT of at least 2 times ULN, as compared with those who maintained normal ALT. Cox regression analysis indicated that age at entry, sex, and maximal ALT level during follow‐up were significant independent factors associated with the development of cirrhosis, HCC, and mortality whereas cirrhosis was also an independent factor for HCC development and mortality. Conclusion: Persistently normal ALT was associated with excellent long‐term prognosis, whereas increasing ALT levels of at least 2 times ULN during follow‐up was associated with increasing morbidity and mortality. ALT of at least 2 times ULN is therefore an appropriate threshold for anti‐HBV therapy, whereas those with ALT 1 to 2 times ULN require liver biopsy for decision. (HEPATOLOGY 2009.)Keywords
This publication has 43 references indexed in Scilit:
- Hepatitis B virus infectionPublished by Elsevier ,2009
- Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen–negative chronic hepatitis B virus infection?Hepatology, 2008
- Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 2008
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatology International, 2008
- Serum aminotransferase activity and mortality risk in a United States communityHepatology, 2008
- Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg‐negative chronic hepatitis B virus infectionJournal of Viral Hepatitis, 2008
- The clinical significance of persistently normal ALT in chronic hepatitis B infectionJournal of Hepatology, 2007
- Predicting response to peginterferon -2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis BGut, 2007
- PGC-1α controls hepatitis B virus through nutritional signalsProceedings of the National Academy of Sciences, 2006
- EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B13–14 September, 2002Geneva, SwitzerlandJournal of Hepatology, 2003